				0.	5. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	
Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/529,115	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	March 24, 2005	
				First Named Inventor	Brian G. Condie	
0.,	(Use as many sheets			Art Unit		
			•	Examiner Name		
Sheet	1	of	1	Attorney Docket Number	18377-0059	

xaminer	Cito	Include name of the author (in CAPITAL LETTERS), title of the articles (when appropriate), title of the item (book,	_			
nitials*	Cite No.1	magazine, journal, serial, symposium, catalog etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T ³			
/DG/		BIEBERICH, 2004 "Integration of Glycosphingolipid Metabolism and Cell-Fate Decisions in Cancer and Stem Cells: Review and Hypothesis," Glycoconjugate Journal 21(6)315-327.				
/DG/		BUCCOLIERO, et al., 2003 "The Roles of Ceramide and Complex Sphingolinids in Neuronal Cell				
/DG/		Function," Pharmacol. Re. 47(5)409-419. TOMAN, et al., 2000 "Role of Ceramide in Neuronal Cell Death and Differentiation," J. Neurotrauma 17(10)891-898.				
			L			
			-			
			H			
			H			
			T			
			L			
			L			
,			H			
			H			
	-					
	-		-			
			H			
			F			
			L			
			-			
			⊢			

EX-Minister, finding it repletifields considered, winship or not coason is in conformance with MMPLF 909. Up-w the through catasin is not in conformance and not Applicant's nature ocitized and separate production designation number (optional). "Applicant's nature of refinalish anguage Translation is suffer Translation is an ITM Translation or information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file only the USPTO to process) and supplication. Confidentiality is governed by 35 U.S. C. 123 and 37 CFR 1.18. SENTO TO. Commissioner for Patents, 190. Dox 1450, Alexand, AV 22313-1450.